Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 12, 2025
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -
Read more at globenewswire.com
